Expert Interview
Digging into the details of AcelRx's 1.1bn peak sales claim for ARX-04
Ticker(s): ACRX, REPHAn anesthesiologist specializing in post operative pain management.
Please describe your current practice and how you treat patients with post operative pain. If you have any relationship with ARX-04 or AcelRx can you please explain that as well?
Added By: joe_mccannWhere do you see ARX-04 fitting into the treatment landscape based on the profile seen in the clinical development program.
Added By: joe_mccannThis drug is being filed as a 505 (b) 2 application based on Sufenta. How do you see the two products comparing to each other? Where does '04 most meaningfully differentiate itself to you?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
